Trial Profile
A Multi-center, Parallel-group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of 4.0 mg/kg Sugammadex Administered at 1-2 PTC in Subjects With Normal or Severely Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; NV Organon
- 19 Nov 2015 New trial record